IVAX Diagnostics, Inc. is headquartered in Miami, Florida and develops, manufactures and markets proprietary diagnostic reagents, instrumentation and software worldwide through its three subsidiaries; Diamedix Corporation, Delta Biologicals S.r.l. and ImmunoVision, Inc.
IVAX Diagnostics, Inc. was created as a result of the merger on March 14, 2001 between b2bstores.com, Inc. and the diagnostic business subsidiary within IVAX Corporation. On January 26, 2006 , IVAX Corporation was merged into a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (Teva). As a result of this merger, Teva, indirectly through its IVAX Corporation subsidiary, owned approximately 72% of IVAX Diagnostics. On September 2, 2008 , a group controlled by two experienced and well-known international medical diagnostics and pharmaceutical industry entrepreneurs, Paul Kennedy and Patrice Debregeas, purchased all of the shares of IVAX Diagnostics' common stock owned by Teva and, accordingly, collectively owns approximately 72% of IVAX Diagnostics. On September 1, 2010, ERBA Diagnostics Mannheim GmbH, an in vitro diagnostics company headquartered in Germany (ERBA), purchased all of the approximately 72% of the outstanding shares of the Company's common stock owned by the group controlled by Messrs. Debregeas and Kennedy. As a result of the share acquisition, ERBA now owns approximately 72.5% of the outstanding shares of the Company's common stock.
IVAX Diagnostics' common stock trades under the ticker symbol IVD on the American Stock Exchange.
Diamedix Corporation develops and manufactures in vitro diagnostics kits that it markets in conjunction with its MAGO® Plus instruments for use in clinical and hospital laboratories.
ImmunoVision, Inc. develops manufactures and markets autoimmune reagents and research products for use in clinical laboratories, research laboratories and other diagnostic manufacturing companies.
Delta Biologicals, S.r.l.